Semaglutide vs Tirzepatide
Single versus dual incretin receptor engagement — the central comparison in current metabolic pharmacology.
Metabolic
Semaglutide
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
Metabolic
Tirzepatide
Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.
Side by side
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Molecular weight | 4113.58 g/mol | 4813.45 g/mol |
| Size class | long peptide | long peptide |
| CAS number | 910463-68-2 | 2023788-19-2 |
| Research area | metabolic | metabolic |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 5mg, 10mg, 20mg | 10mg, 20mg, 30mg |
| Entry price | $44 | $89 |
| Cost per mg | $6.45 | $6.63 |
Mechanism
Semaglutide
Semaglutide is a 31-amino-acid GLP-1 analog structurally modified at position 8 (Aib substitution) to resist DPP-4 degradation, with a C18 fatty diacid chain conjugated via a spacer at Lys26 that promotes albumin binding. These modifications extend its half-life substantially relative to native GLP-1, which has a circulating half-life measured in minutes. It is among the most heavily published peptides in modern metabolic research.
Tirzepatide
Tirzepatide is a synthetic 39-amino-acid peptide engineered from the native GIP sequence with structural modifications conferring agonism at both the GIP and GLP-1 receptors. A C20 fatty diacid moiety supports albumin binding and extended half-life. Its research interest lies substantially in the question of whether dual incretin agonism produces effects distinguishable from GLP-1 monoagonism.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
Semaglutide
Evidence base: extensive, independently replicated, with published receptor-level and pharmacokinetic characterization.
Full research reference →Tirzepatide
Evidence base: strong receptor-level characterization and independent replication; GIP receptor directionality remains genuinely contested.
Full research reference →Research applications
Semaglutide
- Incretin receptor signaling and β-cell response studies
- Gastric emptying and satiety-pathway research in rodent models
- Comparative pharmacokinetics against dual and triple agonists
- Receptor binding affinity and selectivity assays
Tirzepatide
- Dual incretin receptor signaling and biased agonism studies
- Comparative studies against selective GLP-1 agonists
- cAMP accumulation and β-arrestin recruitment assays
- Adipose and hepatic metabolic pathway research
Common questions
What is the difference between Semaglutide and Tirzepatide?
Semaglutide is long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models. Tirzepatide is dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity. They differ in molecular weight (4113.58 vs 4813.45 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, Semaglutide or Tirzepatide?
Semaglutide is lower at approximately $6.45 per milligram at its best tier, against $6.63 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can Semaglutide and Tirzepatide be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should Semaglutide and Tirzepatide be stored?
Store lyophilized powder at -20°C protected from light. Reconstituted solution is stable at 2-8°C for up to 30 days. For Tirzepatide: Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.
Which has the stronger evidence base?
Semaglutide — Evidence base: extensive, independently replicated, with published receptor-level and pharmacokinetic characterization. Tirzepatide — Evidence base: strong receptor-level characterization and independent replication; GIP receptor directionality remains genuinely contested.
All products are intended strictly for laboratory research use. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not a drug, food, or cosmetic.
Comparison generated from NuVida Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.